Toric small aperture intraocular lens with extended depth of focus

Information

  • Patent Grant
  • 11464625
  • Patent Number
    11,464,625
  • Date Filed
    Monday, November 21, 2016
    8 years ago
  • Date Issued
    Tuesday, October 11, 2022
    2 years ago
  • Inventors
  • Original Assignees
  • Examiners
    • Dieterle; Jennifer
    • Shipmon; Tiffany P
    Agents
    • Knobbe, Martens, Olson & Bear, LLP
Abstract
An intraocular lens is provided that includes a refractive element and a mask. The refractive element has a first power in a first meridian and a second power greater than the first power in a second meridian. A magnitude of the first and second powers and a location of the first and second meridians are configured to correct astigmatism in a human eye. The mask is configured to block a substantial portion of light from passing through an annular region thereof and to permit a substantial portion of light to pass through a central aperture thereof to enhance an astigmatism correction rotational misplacement range and depth of focus.
Description
BACKGROUND
Field

This application is directed to ophthalmic devices that can be used to improve vision in patients suffering from astigmatism.


DESCRIPTION OF THE RELATED ART

The human eye functions to provide vision by transmitting and focusing light through the cornea and through the crystalline lens in the eye to form a focused image on a retina. The quality of the focused image depends on many factors including the size and shape of the eye, the transparency of the cornea and the lens, as well as the capability of the lens to accommodate.


The optical power of the eye is a function of the optical power of the cornea and the crystalline lens. In a normal, healthy eye, sharp images of distant objects are formed on the retina. This vision state is called emmetropia. In myopic eyes, images of distant objects are formed at a location in front of the retina. This may be because the eye is abnormally long or the cornea is abnormally steep. In hyperopic eyes, images are formed at a location behind the retina. This may be because the eye is abnormally short or the cornea is abnormally flat. The focusing effect of the eye may be rotationally asymmetric, resulting in an uncompensated cylindrical refractive error referred to as astigmatism.


Some people suffer from cataracts in which the crystalline lens undergoes a loss of transparency. In such cases, the crystalline lens can be removed and replaced with an intraocular lens (IOL). However, commercially approved intraocular lenses do not restore full vision function and even small misplacement in the eye can result in sub-optimal vision correction. As a result, many patients are subject to inconvenient post-operative strategies to cope.


SUMMARY

This application is directed to providing a better outcome for patients undergoing intraocular refractive vision correction. This application discloses devices that can simplify treatment of complex cases, such as patients who have a lack of accommodation, cataract, and/or astigmatism.


In one embodiment, an intraocular lens is provided that includes a refractive element and a mask. The refractive element has a first power in a first meridian and a second power greater than the first power in a second meridian. A magnitude of the first and second powers and a location of the first and second meridians are configured to correct astigmatism in a human eye. The mask is configured to block a substantial portion of light from passing through an annular region thereof and to permit a substantial portion of light to pass through a central aperture thereof to enhance an astigmatism correction rotational misplacement range.


In another embodiment, an intraocular lens is provided that includes a refractive element that is adapted to counter astigmatism in a human eye and a mask. The mask is configured to prevent light from passing through an annular region thereof. The mask is configured to permit a light to pass through a central aperture thereof to increase depth of focus and to increase tolerance to rotational misplacement within the eye by as much as 15 degrees.


In another embodiment a method of correcting astigmatism is provided. In the method, an intraocular lens is placed into an eye of a patient. The intraocular lens has a cylinder power component aligned with a meridian thereof and a mask comprising a small aperture surrounded by an opaque member. It is then confirmed that the meridian of the intraocular lens is aligned within a range exceeding five degrees of a locally minimum power of the eye to reduce astigmatism in the eye such that the eye achieves functional acuity.


Any feature, structure, or step disclosed herein can be replaced with or combined with any other feature, structure, or step disclosed herein, or omitted. Further, for purposes of summarizing the disclosure, certain aspects, advantages, and features of the inventions have been described herein. It is to be understood that not necessarily any or all such advantages are achieved in accordance with any particular embodiment of the inventions disclosed herein. No aspects of this disclosure are essential or indispensable.





BRIEF DESCRIPTION OF THE DRAWINGS

Various embodiments are depicted in the accompanying drawings for illustrative purposes, and should in no way be interpreted as limiting the scope of the embodiments. Furthermore, various features of different disclosed embodiments can be combined to form additional embodiments, which are part of this disclosure.



FIG. 1 schematically illustrates uncorrected and corrected focusing effect along a horizontal meridian of an eye with astigmatism in which the lowest power meridian of the eye is aligned with the horizontal meridian.



FIG. 2 schematically illustrates uncorrected and corrected focusing effect along a vertical meridian of an eye with astigmatism in which the highest power meridian of the eye is aligned with the vertical meridian.



FIG. 3 illustrates a power distribution of a refractive element of an intraocular lens (IOL) configured to correct for rotationally asymmetric refractive error illustrated in FIGS. 1 and 2.



FIGS. 4A-4D illustrate an embodiment of an IOL having a refractive element and a mask coupled with the refractive element.



FIG. 5A illustrates an embodiment of a mask.



FIG. 5B illustrates another embodiment of the mask.



FIG. 6 schematically illustrates the depth of focus extending effect of the masks of FIGS. 5A and 5B.



FIG. 7 shows simulated defocus performance of a monofocal IOL with corneal aberration correction compared with the same IOL additionally incorporating a small aperture optic.



FIG. 8 shows simulated cylinder performance of a monofocal IOL with corneal aberration correction compared with the same IOL additionally incorporating a small aperture optic.



FIG. 9 shows simulated defocus performance of a monofocal tonic IOL in an eye system with cylinder cornea compared with the same IOL additionally incorporating a small aperture optic.



FIG. 10 shows simulated cylinder performance of a monofocal tonic IOL in an eye system with cylinder at the cornea and additional cylinder at the IOL plane compared with the same IOL additionally incorporating a small aperture optic.



FIG. 11 shows simulated rotational misalignment performance of a monofocal toric IOL in an eye system with cylinder at the cornea compared with the same IOL additionally incorporating a small aperture optic.



FIG. 12 is a schematic diagram of an eye showing increased tolerance to misplacement as provided by certain embodiments herein.





DETAILED DESCRIPTION

A patient with astigmatism has unequal optical power at different rotational positions of the eye. The power of the eye is greater in some meridians of the eye than in other meridians. Patients who undergo IOL implantation surgery may suffer from astigmatism. This may be because even if the IOL has perfectly symmetric optics, the cornea of the eye in which the IOL is placed may be formed in a way providing uneven, rotationally asymmetric powers.



FIGS. 1 and 2 illustrate a simple example of how an astigmatic eye 10 converges light passing through the lens. FIG. 1 illustrates a horizontal meridian H of the eye 10. Light incident on the horizontal meridian passes through the crystalline lens 18 and converges behind the retina 14. The solid lines show that the light passing along the horizontal meridian H is focused at a location rearward of the retina 14 by a first amount. FIG. 2 illustrates a vertical meridian V of the eye 10. In FIG. 2, solid lines illustrate that light passing along the vertical meridian V is focused at a location rearward of the retina 14 by a second amount greater than the first amount, which is the optical effect of astigmatism.



FIG. 3 shows a refractive element 100 that can correct for the rotational asymmetry of refractive power in an eye that causes astigmatism. The refractive element 100 includes a surface 104 that has a refractive power. That is, the surface 104 is configured to cause rays being refracted in an astigmatic eye and through the element 100 to converge at a common focal point. The surface 104 can have a refractive index that causes such convergence, can be curved to cause such convergence or can combine refractive index and curvature together or with other optical effects to cause such convergence. In one embodiment, the surface 104 has a first curvature 108 and a second curvature 112. The first curvature 108 is less than the second curvature 112. As a result, the first curvature 108 has less optical power than the second curvature 112. The second curvature 112 induces more convergence of the rays that are incident on the surface 104 along a line of the second curvature 112 than the first curvature 108.


If the refractive element 100 is properly placed in the astigmatic eye 10 illustrated in FIGS. 1 and 2, the refractive element 100 can correct the astigmatism. The refractive element 100 can be placed in the eye 10 such that the first curvature 108 is aligned with the horizontal meridian H which is illustrated in FIG. 1. When so placed, the first curvature 108 corrects the relatively smaller hyperopic error on the horizontal meridian H of the eye 10 by a first amount. The refractive element 100 can be placed in the eye 10 such that the second curvature 112 is aligned with the vertical meridian V which is illustrated in FIG. 2. When placed such that the second curvature 112 is aligned with the vertical meridian, the relatively larger hyperopic error is corrected by a larger amount than was corrected in the horizontal meridian H. As a result, the rays on both meridians are brought into focus at the same location. An additional power can be provided if needed to shift the focal plane to the retina as illustrated by the solid converging lines in FIGS. 1 and 2.



FIG. 3 shows the refractive element 100 surrounded by dashed lines. As discussed further below, other components of an IOL incorporating the refractive element 100 can be coupled with the refractive element 100 either prior to implantation or during the course of the useful life of the IOL incorporating the refractive element 100.


Intraocular Lens


As shown in FIGS. 4A-4D, an intraocular lens 1000 includes an optic 1004 and a mask 1012. The optic 1004 can be formed from an optically transmissive material, while the mask 1012 can be formed from an opaque material. The optic 1004 can include the refractive element 100 to correct refractive errors, such as rotationally asymmetric power, e.g., astigmatism. The optic 1004 can include other structures to improve the overall visual performance of the IOL 1000 in addition to the refractive element 100.


The optic 1004 can be monofocal or multifocal and it can have positive or negative optical power. The optic 1004 may be aspheric or any other configuration as the context may dictate. In various embodiments the optic 1004 has a cylinder power or other rotationally asymmetric power such that the optic 1004 can correct for astigmatism of an eye as discussed above. In some implementations, the greatest thickness of the optic 1004 is at the center of the optic 1004. In other implementations, the optic 1004 may have a reduced thickness at its center, which is further described in U.S. Publication No. 2011/0040376, filed Aug. 13, 2010, which is hereby incorporated by reference in its entirety herein. The optic 1004 may be substantially circular with an outer diameter between about 5.0 mm and about 8.0 mm, such as about 6.0 mm. A central thickness of the optic 1004 can be less than or equal to about 1.0 mm, such as between about 0.75 mm and about 1.0 mm.


The intraocular lens 1000 may include one or more haptics 1008 (e.g., one, two, three, four, or more) to prevent the intraocular lens 1000 from moving or rotating within the eye. As used herein the term “haptic” is intended to be a broad term encompassing struts and other mechanical structures that can be apposed against an inner surface of an eye and mounted to an optic to securely position an intraocular lens in an optical path of an eye. The haptics 1008 can be a variety of shapes and sizes depending on the location the intraocular lens 1000 is implanted in the eye. The haptics 1008 may be C-shaped, J-shaped, plate design, or any other design. The haptics 1008 may be manufactured substantially flat or vaulted with respect to the optic. Variations on the shape of the optic and the haptics can be found in U.S. Publication No. 2011/0040376, filed Aug. 13, 2010, which is hereby incorporated by reference in its entirety herein.


The mask 1012 can be formed on an anterior surface 1016 of the optic 1004 (see FIGS. 4A-4D), on a posterior surface 1020 of the optic 1004, or embedded within the optic 1004. When the mask 1012 is embedded within the optic 1004, the mask 1012 can be formed substantially at the midway line between the posterior 1020 and anterior surfaces 1016 of the optic 1004. But the mask 1012 can also be formed at other locations within the optic 1004. Additional information regarding the manufacturing of such intraocular lenses can be found in PCT/US2016/055207, filed Oct. 3, 2016, which is hereby incorporated by reference in its entirety herein.


Mask



FIG. 5A illustrates a mask 2034a having an annular region 2036a surrounding an aperture 2038a substantially centrally located on the mask 2034a. An anterior surface of the annular region 2036a can have a curvature from the outer periphery to the inner periphery of the annular region 2036a, and the posterior surface of the annular region 2036a can have a similar curvature. FIG. 5B shows that the mask 2034b can be flat in some embodiments. The mask 2034b can include an annular region 2034b surrounding an aperture 2038b substantially centered on the optical axis 2039b of the mask 2034b. Although the features described below are described with respect to the mask 2034a, one or the more of the features may be applied to the mask 2034b.


In some embodiments, the outer periphery of the mask 2034a is generally circular with an outer diameter of at least about 3 mm and less than about 6 mm. In some embodiments, the diameter of the outer periphery of the mask 2034a is at least about 3 mm and less than or equal to about 4 mm.


A thickness of the mask 2034a can be constant or can vary between the inner periphery (near the aperture) and the outer periphery. For example, the thickness may increase from an outer periphery and/or inner periphery of the mask 2034a and toward a radial midline of the annular region 2036a. In general, the thickness at any location of the mask 2034a can be less than or equal to about 200 microns, or less than or equal to about 100 microns, but preferably between about 1 micron and about 20 microns. For example, the thickness of the mask 2034a can be within the range: from about 1 micron to about 40 microns, from about 5 microns to about 20 microns, from about 5 microns to about 15 microns. In some implementations, the thickness of the mask 2034a can be within about two microns of: about 15 microns, about 10 microns, about 8 microns, or about 5 microns.


The aperture 2038a can transmit substantially all incident visible light along the optical axis 2039a. For example, the aperture 2038a can be a through-hole in the annular region 2036a or a substantially light transmissive (e.g., transparent to visible light) portion thereof. The aperture 2038a can be substantially circular and/or substantially centered around the optical axis 2039a of the mask 2034a. The size of the aperture 2038a can be any size that is effective to increase the depth of focus of an eye of a patient with presbyopia. In particular, the size of the aperture 2038a can be dependent on the location of the mask 2034a within the eye (e.g., distance from the retina). In some implementations, the aperture 2038a can have a diameter of at least about 0.85 mm and less than or equal to about 2.8 mm, at least about 1.1 mm and less than or equal to about 1.6 mm, or at least about 1.3 mm and less than or equal to about 1.4 mm.


The annular region 2036a can prevent transmission of substantially all or at least a portion of the spectrum of the incident visible light (e.g., radiant energy in the electromagnetic spectrum that is visible to the human eye) and/or the spectrum of non-visible light (e.g., radiant energy outside the range visible to humans). Preventing transmission of visible light through the annular region 2036a can block light that would not converge at the retina and fovea to form a sharp image. FIG. 6 illustrates this effect. In particular, the IOL 1000 is placed in the capsular bag of the eye 10. The mask 1012 is centered on the optical axis of the eye 10. Rays that would not converge on the retina 14 are illustrated by the dash lines. These rays are blocked by the annular region 2036a or the annular region 2036b of the mask 1012 and thus are prevented from degrading vision by causing a blur on the retina. Rays that converge on the retina 14 pass through the aperture of the mask 1012. A crisp image over a range of distances is provided by this focused light as discussed further below.


In some implementations, the annular region 2036a can prevent transmission of at least about: 90 percent of incident visible light, 92 percent of incident visible light, 95 percent of incident visible light, 98 percent of all incident visible light, or 99 percent of all incident visible light. The annular region 2036a can transmit no more than about: 10 percent of incident visible light, 8 percent of incident visible light, percent of incident visible light, 3 percent of incident visible light, 2 percent of incident visible light, or 1 percent of incident visible light.


In some embodiments, opacity of the annular region 2036a is achieved because the material used to make mask 2034a is naturally opaque. In other embodiments, the material used to make the mask 2034a may be naturally substantially clear but treated with a dye or other pigmentation agent (e.g., carbon black). In some embodiments, the mask is made of the same material as the lens body, with the addition of dye or other pigmentation agent. In other embodiments, the mask is made of a different material from the lens body.


Further variations of masks can be found in U.S. application Ser. No. 62/237,429, filed Oct. 5, 2015, U.S. Pat. No. 7,628,810, filed May 26, 2004, U.S. Publication No. 2012/0143325, filed Feb. 19, 2012, U.S. Publication No. 2011/0040376, filed Aug. 13, 2010; U.S. Publication No. 2013/0268071, filed Nov. 30, 2012; U.S. Publication No. 2014/0264981; U.S. Publication No. 2015/0073549, filed Aug. 7, 2014; U.S. Pat. No. 5,662,706, filed Jun. 14, 1996; U.S. Pat. No. 5,905,561, filed Jun. 14, 1996; and U.S. Pat. No. 5,965,330, filed Dec. 6, 1996, all of which are hereby incorporated by reference in their entirety herein.


Discussion of Simulation Tests



FIG. 7, upper row, is a Zemax optical simulation of the optical performance of a 21 diopter monofocal IOL. In the simulation, corneal aberration is corrected and the simulation assumes a realistic polychromatic model eye, with a 3 mm pupil. The left-most box shows the visual acuity for 0 diopter defocus. The acuity illustrated is acceptable at 20/20 or greater. The second box from the left shows the visual acuity for a −0.5 diopter defocus using the same lens and model used in the left-most box. One can see that the performance has declined, but the threshold acuity level is still at about 20/20. The third box from the left shows the visual acuity for a −1.0 diopter defocus using the same lens and simulation model used in generating the left-most box. One can see that this box does not register any level of visual acuity and thus the IOL is completely ineffective at this and greater defocus amounts.



FIG. 7, lower row, is a Zemax optical simulation of the optical performance of an IOL that has a small aperture mask disposed therein for extended depth of focus. The small aperture optic can have a 1.36 mm working aperture. The IOL had optimal focus. The simulation used a realistic polychromatic model eye with a 3 mm pupil. The left-most box shows the visual acuity for 0 diopter defocus, which is acceptable at 20/20 or greater. In contrast to the upper row, each of the defocus positions in the lower row from the left most box toward the right from −0.5 diopter, −1.0 diopter, −1.5 diopter and −2.0 diopter defocus show a 20/20 visual acuity or better. This simulation confirms the effectiveness of the small aperture optic illustrated in FIG. 6.



FIG. 8, upper row, is a Zemax optical simulation of the optical performance of a 21 diopter monofocal IOL correcting corneal aberration using a realistic polychromatic model eye, with a 3 mm pupil. The left-most box shows the visual acuity for 0 diopter added cylinder power. The acuity illustrated is acceptable at 20/20 or greater. The third box from the left shows the visual acuity for a −0.5 diopter addition of cylinder power using the same lens and model used in the left-most box. One can see that the performance has declined, but the threshold acuity level is still at about 20/20. The fifth box from the left shows the visual acuity for a −1.0 diopter addition of cylinder power using the same lens and model used in the left-most box. One can see that this box does not register any useful level of visual acuity and thus the IOL is completely ineffective at this and greater amounts of cylinder.



FIG. 8, lower row, is a Zemax optical simulation of an IOL with a small aperture mask that provides extended depth of focus. The mask was provided with a 1.36 working aperture and the IOL with optimal focus. The model again was constructed using a realistic polychromatic model eye with a 3 nm pupil. The left-most box shows the visual acuity for 0 added cylinder power and in this box the acuity illustrated is acceptable at 20/20 or greater. The third and fifth boxes from the left show the visual acuity for a −0.5 and −1.0 diopter added cylinder power using the same lens and model used in the left-most box, lower row. One can see that the performance has declined, but the threshold acuity level is still at about 20/20. In fact the performance of the small aperture IOL remains acceptable even to the right-most box which illustrates performance with −1.5 diopter of cylinder. FIG. 8 thus shows that a small aperture IOL can provide vision correction for small amounts of astigmatism even up to −1.5 diopters of added cylinder.



FIG. 9 shows the performance of a tonic IOL. In particular, FIG. 9, upper row, is a Zemax optical simulation of the optical performance of a 3 diopter tonic monofocal IOL using a realistic polychromatic model eye, with a 3 mm pupil and with a toric cornea. The performance of the tonic IOL is similar to that of the monofocal IOL illustrated in FIG. 7. That is, it can tolerate about −0.5 diopter defocus. But greater amounts of defocus degrade the visual acuity too much for the tonic IOL to provide functional visual acuity. In contrast, FIG. 9, lower row, shows that astigmatism in an eye can be more robustly corrected by a 3 diopter tonic IOL with a small aperture optic, e.g., having a 1.36 mm working aperture with the IOL having optimal focus. The lower row shows that the tonic IOL with small aperture optic can still perform well at up to −2.0 diopters of defocus.



FIG. 10 shows a further comparison of the performance of a 21 diopter monofocal toric IOL and the same IOL with a small aperture optic, e.g., an optic having a 1.36 mm working aperture. FIG. 10 shows the ability of these two IOLs to sustain visual acuity when working with progressively more additional cylinder power. The upper row shows that a tonic IOL can sustain acceptable visual acuity up to an additional −0.5 diopter of cylinder. The lower row shows that the toric IOL with a small aperture optic can perform well even when subject to up to −1.5 diopter of cylinder. This means that even in a patient with progressively worsening astigmatism, the toric IOL with small aperture optic can continue to provide good vision without additional lenses or procedures for much longer than the standard toric IOL.



FIG. 11 shows a further comparison of the performance of a 21 diopter monofocal toric IOL and the same IOL with a small aperture optic, an optic having a 1.36 mm working aperture. FIG. 11 shows the ability of these two IOLs to sustain rotational misplacement. The upper row shows that a tonic IOL can sustain a 5 degree rotational misplacement or misalimment. Beyond this amount, the visual acuity delivered by the standard tonic IOL is insufficient. The lower now shows that the toric IOL with a small aperture optic can perform well at up to 15 degrees of rotational misplacement or misalignment. This means that even where an IOL implantation procedure was not according to a pre-operative plan, the IOL will perform well. This is because the IOL has a much wider window of acceptable rotational placement. The lower row of FIG. 11 suggests that a 30 degree window can be provided within which a patient will have acceptable visual acuity. This is three times larger than the much more limited range of placement that a standard IOL can tolerate. This represents a significant improvement in toric IOL design, enhancing the robustness of the IOL such that the chance of a poor outcome even if placement is sub-optimal is greatly reduced.


The simulation performance can be summarized as follows:














IOL Configuration













Standard





Standard
Monofocal
EDOF Small
EDOF Small


Performance
Monofocal
Toric
Aperture
Aperture Toric


Measurement
IOL
IOL
IOL
IOL





Tolerance to

≤0.5 D


≤0.5 D


≤1.5 D

 ±≤1.5 D


Astigmatism






Tolerance to
N/A
±≤5°
N/A
±≤15°


Angular






Rotational






Placement






Depth of Focus
±≤0.5 D
±≤0.5 D
±≤2.0 D
±≤2.0 D










FIG. 12 schematically illustrates aspects of certain embodiments. In particular, a cylinder power exists in the eye 10 prior to correction causing astigmatism. In this case, the power in the vertical meridian V is noticeably less than in the horizontal meridian H. The IOL 1000 including the refractive element 100 is provided and is placed in the eye 10. As discussed above, the refractive element 100 has different powers in different portions. For example, a meridian of the refractive element 100 can have the first curvature 108 and another meridian of the element 100 can have the second curvature 112 larger than the first curvature. The curvatures 108, 112 are along perpendicular meridians, but could be at other angles to each other as a function of the power profile of the eye. As discussed above, the steeper second curvature 112 induces more convergence. Accordingly, the second curvature 112 should optimally be aligned with the vertical meridian V of the eye 10 so that the locally lower power of the eye 10 is compensated by the second curvature 112 to enable the vertical and horizontal meridians V, H to converge at the same location. However, as shown, the refractive element 100 is rotationally offset from the optimal aligned position. Advantageously, the IOL 1000 is enabled by the combination of a tone configuration of the refractive element 100 and the mask 1012 to have a much larger than conventional acceptable rotational offset from the optimal position. FIG. 12 shows in the shaded pie-shaped region that there is an acceptable acuity over a large IOL placement range. In this embodiment, the range extends on both sides, e.g., symmetrically, of the optimal (vertical) position. As such IOL 1000 provides an increase in tolerance to rotational misplacement. The range extends beyond the angle of misplacement of the IOL 1000. In the conventional IOL, the range would be much less, for example between the position of the second curvature 112 and the vertical meridian V preventing the convention IOL when placed as shown in FIG. 12 from providing functional visual acuity.


Terminology


Conditional language, such as “can,” “could,” “might,” or “may,” unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements, and/or steps. Thus, such conditional language is not generally intended to imply that features, elements, and/or steps are in any way required for one or more embodiments or that one or more embodiments necessarily include logic for deciding, with or without user input or prompting, whether these features, elements, and/or steps are included or are to be performed in any particular embodiment.


The terms “comprising,” “including,” “having,” and the like are synonymous and are used inclusively, in an open-ended fashion, and do not exclude additional elements, features, acts, operations, and so forth. Also, the term “or” is used in its inclusive sense (and not in its exclusive sense) so that when used, for example, to connect a list of elements, the term “or” means one, some, or all of the elements in the list.


The terms “approximately,” “about,” and “substantially” as used herein represent an amount close to the stated amount that still performs a desired function or achieves a desired result. For example, the terms “approximately,” “about,” and “substantially” may refer to an amount that is within less than 10% of the stated amount, as the context may dictate.


The ranges disclosed herein also encompass any and all overlap, sub-ranges, and combinations thereof. Language such as “up to,” “at least,” “greater than,” “less than,” “between” and the like includes the number recited. Numbers preceded by a term such as “about” or “approximately” include the recited numbers. For example, “about 3 mm” includes “3 mm.”


Although certain embodiments and examples have been described herein, it will be understood by those skilled in the art that many aspects of the methods and IOL shown and described in the present disclosure may be differently combined and/or modified to form still further embodiments or acceptable examples. All such modifications and variations are intended to be included herein within the scope of this disclosure. A wide variety of designs and approaches are possible. No feature, structure, or step disclosed herein is essential or indispensable.


For purposes of this disclosure, certain aspects, advantages, and novel features are described herein. It is to be understood that not necessarily all such advantages may be achieved in accordance with any particular embodiment. Thus, for example, those skilled in the art will recognize that the disclosure may be embodied or carried out in a manner that achieves one advantage or a group of advantages as taught herein without necessarily achieving other advantages as may be taught or suggested herein.


Moreover, while illustrative embodiments have been described herein, the scope of any and all embodiments having equivalent elements, modifications, omissions, combinations (e.g., of aspects across various embodiments), adaptations and/or alterations as would be appreciated by those skilled in the art based on the present disclosure. The limitations in the claims are to be interpreted broadly based on the language employed in the claims and not limited to the examples described in the present specification or during the prosecution of the application, which examples are to be construed as non-exclusive. Further, the actions of the disclosed processes and methods may be modified in any manner, including by reordering actions and/or inserting additional actions and/or deleting actions. It is intended, therefore, that the specification and examples be considered as illustrative only, with a true scope and spirit being indicated by the claims and their full scope of equivalents.

Claims
  • 1. An intraocular lens comprising: a toric refractive element adapted to counter astigmatism in a human patient's eye;one or more haptics configured to position the intraocular lens in the eye, the one or more haptics extending from a fixed end disposed at a periphery of the toric refractive element to a free end adapted to contact an inner surface of the eye, the one or more haptics forming an anterior edge of the intraocular lens when implanted in the eye; anda mask configured to prevent a substantial portion of light from passing through an annular region thereof and to permit light to pass through a central aperture thereof to increase depth of focus, a diameter of the central aperture is at least 0.85 mm and less than or equal to 2.8 mm,wherein a combination of the toric refractive element and the mask is configured to increase tolerance to rotational misplacement within the patient's eye within a 30 degree window.
  • 2. The intraocular lens of claim 1, wherein the mask is coupled with a face of an optic incorporating the mask.
  • 3. The intraocular lens of claim 2, wherein the mask is formed on a piggyback IOL configured to couple with the eye to place the mask on the face of the optic.
  • 4. The intraocular lens of claim 1, wherein the mask is embedded in an optic comprising the refractive element.
  • 5. The intraocular lens of claim 1, wherein the mask comprises a plurality of small holes disposed through the annular region to secure the mask to an optic including the refractive element.
  • 6. The intraocular lens of claim 1, wherein the mask is configured to increase depth of focus by a magnitude equivalent to up to 2 diopters of add power.
  • 7. The intraocular lens of claim 1, wherein the refractive element comprises a rotational alignment feature.
  • 8. The intraocular lens of claim 1, wherein the intraocular lens is configured to maintain visual acuity of at least 20/20 from 0.0 diopters to +/− 2.0 diopters of defocus.
  • 9. The intraocular lens of claim 1, wherein the mask comprises an elastic material.
  • 10. The intraocular lens of claim 1, wherein the 30 degree window is +/− 15 degrees.
  • 11. The intraocular lens of claim 1, wherein the intraocular lens is a monofocal intraocular lens.
  • 12. The intraocular lens of claim 1, wherein the one or more haptics are vaulted with respect to the refractive element.
  • 13. The intraocular lens of claim 1, wherein the one or more haptics are flat with respect to the refractive element.
  • 14. An intraocular lens comprising: a toric refractive element adapted to counter astigmatism in a human patient's eye;one or more haptics configured to position the intraocular lens in the eye, the one or more haptics extending from a fixed end disposed at a periphery of the toric refractive element to a free end adapted to contact an inner surface of the eye, the toric refractive element forming an anterior edge of the intraocular lens when implanted in the eye; anda mask configured to block a substantial portion of light from passing through an annular region thereof and to permit a substantial portion of light to pass through a central aperture thereof to increase depth of focus;wherein the intraocular lens is configured to maintain visual acuity of at least 20/20 within +/− 15 degrees of rotational misplacement.
  • 15. The intraocular lens of claim 14, wherein the one or more haptics are vaulted with respect to the refractive element.
  • 16. The intraocular lens of claim 14, wherein the one or more haptics are flat with respect to the refractive element.
RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 62/259,524, filed Nov. 24, 2015, which is hereby incorporated by reference in its entirety herein.

PCT Information
Filing Document Filing Date Country Kind
PCT/US2016/063181 11/21/2016 WO
Publishing Document Publishing Date Country Kind
WO2017/091520 6/1/2017 WO A
US Referenced Citations (471)
Number Name Date Kind
2350421 Schoder et al. Jun 1944 A
2470927 Hale, Jr. May 1949 A
3034403 Neefe May 1962 A
3270099 Camp Aug 1966 A
3458870 Stone Aug 1969 A
3578850 Grant May 1971 A
3776230 Neefe Dec 1973 A
3794414 Wesley Feb 1974 A
3877502 Hunckler Apr 1975 A
3996627 Deeg et al. Dec 1976 A
4010496 Neefe Mar 1977 A
4104338 Guerrieri Aug 1978 A
4116439 Chavarrla et al. Sep 1978 A
4210391 Cohen Jul 1980 A
4298996 Barnet Nov 1981 A
4340283 Cohen Jul 1982 A
4402396 Graham Sep 1983 A
4402579 Poler Sep 1983 A
4423728 Lieberman Jan 1984 A
4435050 Poler Mar 1984 A
4450593 Poler May 1984 A
4470159 Peyman Sep 1984 A
4505855 Bruns et al. Mar 1985 A
4512039 Lieberman Apr 1985 A
4563565 Kampfer et al. Jan 1986 A
4575373 Johnson Mar 1986 A
4596578 Kelman Jun 1986 A
4607617 Choyce Aug 1986 A
4624669 Grendahl Nov 1986 A
4639105 Neefe Jan 1987 A
4646720 Peyman et al. Mar 1987 A
4655774 Choyce Apr 1987 A
4665913 Esperance, Jr. May 1987 A
4669466 L'Esperance Jun 1987 A
4669834 Richter Jun 1987 A
4676790 Kern Jun 1987 A
4676791 LeMaster et al. Jun 1987 A
4678422 York Jul 1987 A
4701038 Neefe Oct 1987 A
4715858 Lindstrom Dec 1987 A
4744647 Meshel et al. May 1988 A
4767647 Bree Aug 1988 A
4795462 Grendahl Jan 1989 A
4798608 Grendahl Jan 1989 A
4799784 Safir Jan 1989 A
4799931 Lindstrom Jan 1989 A
4807623 Lieberman Feb 1989 A
4813955 Achatz et al. Mar 1989 A
4815690 Shepherd Mar 1989 A
4817789 Paul Apr 1989 A
4830855 Stewart May 1989 A
4842599 Bronstein Jun 1989 A
4842782 Portney Jun 1989 A
4851003 Lindstrom Jul 1989 A
4863466 Schlegel Sep 1989 A
4881860 Kanazawa Nov 1989 A
4903695 Warner et al. Feb 1990 A
4907586 Bille et al. Mar 1990 A
4928815 Paul May 1990 A
4955904 Atebara et al. Sep 1990 A
4976732 Vorosmarthy Dec 1990 A
4994080 Shepard Feb 1991 A
5013319 Davis May 1991 A
5030230 White Jul 1991 A
5034166 Rawlings et al. Jul 1991 A
5041133 Sayano et al. Aug 1991 A
5055602 Melpolder Oct 1991 A
5087015 Galley Feb 1992 A
5090955 Simon Feb 1992 A
5092880 Ohmi Mar 1992 A
5094521 Jolson et al. Mar 1992 A
5098443 Parel et al. Mar 1992 A
5108427 Majercik et al. Apr 1992 A
5112328 Taboada et al. May 1992 A
5120120 Cohen Jun 1992 A
5120121 Rawlings et al. Jun 1992 A
5137441 Fogarty Aug 1992 A
5147395 Willis Sep 1992 A
5171318 Gibson et al. Dec 1992 A
5185107 Blake Feb 1993 A
5188494 Hatin Feb 1993 A
5192316 Ting Mar 1993 A
5196026 Barrett et al. Mar 1993 A
5213749 Huss et al. May 1993 A
5260727 Oksman et al. Nov 1993 A
5266241 Parekh Nov 1993 A
5269795 Arnott Dec 1993 A
5269812 White Dec 1993 A
5274404 Michael Dec 1993 A
5288436 Liu et al. Feb 1994 A
5290892 Namdaran et al. Mar 1994 A
5292514 Capecchi et al. Mar 1994 A
5300116 Chirila et al. Apr 1994 A
5312330 Klopotek May 1994 A
5314439 Sugita May 1994 A
5314961 Anton et al. May 1994 A
5332802 Kelman et al. Jul 1994 A
5336261 Barrett et al. Aug 1994 A
5354331 Schachar et al. Oct 1994 A
5358520 Patel Oct 1994 A
5372580 Simon et al. Dec 1994 A
5391201 Barrett et al. Feb 1995 A
5441511 Hanna Aug 1995 A
5474548 Knopp et al. Dec 1995 A
5507740 O'Donnell, Jr. Apr 1996 A
5507806 Blake Apr 1996 A
5547468 Simon et al. Apr 1996 A
D375245 Irving Nov 1996 S
5578080 McDonald Nov 1996 A
5603774 LeBoeuf et al. Feb 1997 A
5607437 Simon et al. Mar 1997 A
5624456 Hellenkamp Apr 1997 A
5627613 Kaneko May 1997 A
5628794 Lindstrom May 1997 A
5628795 Langerman May 1997 A
5647865 Swinger Jul 1997 A
5652638 Roffman et al. Jul 1997 A
5653752 Silvestrini et al. Aug 1997 A
5662706 Legerton et al. Sep 1997 A
5674284 Chang et al. Oct 1997 A
5693268 Widman et al. Dec 1997 A
5697923 Poler Dec 1997 A
5702440 Portney Dec 1997 A
5708049 Katagiri et al. Jan 1998 A
5713957 Steele et al. Feb 1998 A
5722971 Peyman Mar 1998 A
5725575 O'Donnell, Jr. Mar 1998 A
5728156 Gupta et al. Mar 1998 A
5746558 Nygren et al. May 1998 A
5752967 Kritzinger et al. May 1998 A
5757458 Miller et al. May 1998 A
5769889 Kelman Jun 1998 A
5774202 Abraham et al. Jun 1998 A
5786883 Miller et al. Jul 1998 A
5824086 Silvestrini Oct 1998 A
5837156 Cumming Nov 1998 A
5843105 Mathis et al. Dec 1998 A
5864128 Plesko Jan 1999 A
5870167 Knopp et al. Feb 1999 A
5876442 Lipshitz et al. Mar 1999 A
5895610 Chang et al. Apr 1999 A
5905561 Lee May 1999 A
5910537 Feingold et al. Jun 1999 A
5913898 Feingold et al. Jun 1999 A
5919185 Peyman Jul 1999 A
5925294 Shibuya Jul 1999 A
5964748 Peyman Oct 1999 A
5964776 Peyman Oct 1999 A
5965330 Evans et al. Oct 1999 A
5980040 Xu et al. Nov 1999 A
6007579 Lipshitz et al. Dec 1999 A
6017121 Chateau et al. Jan 2000 A
6063073 Peyman May 2000 A
6090141 Lindstrom Jul 2000 A
6102946 Nigam Aug 2000 A
6106553 Feingold et al. Aug 2000 A
6110166 Juhasz et al. Aug 2000 A
6138307 McDonald Oct 2000 A
6152959 Portney Nov 2000 A
6164777 Li et al. Dec 2000 A
6171336 Sawusch Jan 2001 B1
6178593 Carlson Jan 2001 B1
6197019 Peyman Mar 2001 B1
6201036 Fedorov et al. Mar 2001 B1
6203538 Peyman Mar 2001 B1
6210401 Lai Apr 2001 B1
6217571 Peyman Apr 2001 B1
6217596 Farah Apr 2001 B1
6221067 Peyman Apr 2001 B1
6228113 Kaufman May 2001 B1
6228114 Lee May 2001 B1
6228115 Hoffmann et al. May 2001 B1
6264648 Peyman Jul 2001 B1
6277146 Peyman et al. Aug 2001 B1
6280470 Peyman Aug 2001 B1
6280471 Peyman et al. Aug 2001 B1
6302877 Ruiz Oct 2001 B1
6304390 Takanashi Oct 2001 B1
6308590 Berto Oct 2001 B1
6335190 Zhou et al. Jan 2002 B1
6361560 Nigam Mar 2002 B1
6376153 Uchikawa et al. Apr 2002 B2
6387379 Goldberg et al. May 2002 B1
6391230 Sarbadhikari May 2002 B1
6416179 Lieberman et al. Jul 2002 B1
6423093 Hicks et al. Jul 2002 B1
6432246 Blake Aug 2002 B1
6436092 Peyman Aug 2002 B1
6458141 Peyman Oct 2002 B1
6461384 Hoffmann et al. Oct 2002 B1
6469844 Iwase et al. Oct 2002 B1
6480346 Funakoshi Nov 2002 B2
6491637 Foster et al. Dec 2002 B2
6497700 LaHaye Dec 2002 B1
6515006 Horn Feb 2003 B2
6533416 Fermigier et al. Mar 2003 B1
6551307 Peyman Apr 2003 B2
6554424 Miller et al. Apr 2003 B1
6554860 Hoffmann et al. Apr 2003 B2
6555103 Leukel et al. Apr 2003 B2
6575573 Lai et al. Jun 2003 B2
6581993 Nigam Jun 2003 B2
6588902 Isogai Jul 2003 B2
6589280 Koziol Jul 2003 B1
6607527 Ruiz et al. Aug 2003 B1
6613088 Babizhayev Sep 2003 B1
6638304 Azar Oct 2003 B2
6649722 Rosenzweig et al. Nov 2003 B2
6655804 Streibig Dec 2003 B2
6692126 Xie et al. Feb 2004 B1
6702807 Peyman Mar 2004 B2
6726322 Andino et al. Apr 2004 B2
6740116 Morcher May 2004 B2
6755858 White Jun 2004 B1
6786926 Peyman Sep 2004 B2
6811256 Becherer et al. Nov 2004 B1
6855163 Peyman Feb 2005 B2
6874886 Miller et al. Apr 2005 B2
6899424 Miller et al. May 2005 B2
6949093 Peyman Sep 2005 B1
6951556 Epstein Oct 2005 B2
6966648 Miller et al. Nov 2005 B2
6989008 Peyman Jan 2006 B2
6997428 Andino et al. Feb 2006 B1
7001374 Peyman Feb 2006 B2
7008447 Koziol Mar 2006 B2
7025455 Roffman Apr 2006 B2
7061693 Zalevsky Jun 2006 B2
7099057 Parker et al. Aug 2006 B2
7276080 Murakami et al. Oct 2007 B2
7287852 Fiala Oct 2007 B2
7364674 Hoover Apr 2008 B1
7399811 Mentak et al. Jul 2008 B2
7404637 Miller et al. Jul 2008 B2
7404638 Miller et al. Jul 2008 B2
7446157 Mentak et al. Nov 2008 B2
7455404 Bandhauer et al. Nov 2008 B2
7455691 Feingold et al. Nov 2008 B2
7462193 Nagamoto Dec 2008 B2
7477452 Tsuruma Jan 2009 B2
7491350 Silvestrini Jan 2009 B2
7497866 Perez Mar 2009 B2
7628810 Christie et al. Dec 2009 B2
7632431 Ghazizadeh et al. Dec 2009 B2
7641337 Altmann Jan 2010 B2
7645299 Koziol Jan 2010 B2
7745555 Mentak et al. Jun 2010 B2
7780290 Zhao Aug 2010 B2
7842367 Mentak Nov 2010 B2
7976577 Silvestrini Jul 2011 B2
D645337 Hsu et al. Sep 2011 S
8043371 Paul et al. Oct 2011 B2
8048972 Mentak et al. Nov 2011 B2
8079706 Silvestrini et al. Dec 2011 B2
D656526 Christie et al. Mar 2012 S
8157374 Bandhauer et al. Apr 2012 B2
8241354 Hong et al. Aug 2012 B2
8287592 Silvestrini Oct 2012 B2
8343215 Miller et al. Jan 2013 B2
D681086 Christie et al. Apr 2013 S
8420753 Mentak et al. Apr 2013 B2
8439498 Zhao et al. May 2013 B2
8460374 Christie et al. Jun 2013 B2
8562131 Zhao Oct 2013 B2
8604098 Boydston et al. Dec 2013 B2
8740978 Weeber et al. Jun 2014 B2
8747466 Weeber et al. Jun 2014 B2
8752958 Miller et al. Jun 2014 B2
8633292 Hu et al. Jul 2014 B2
8814934 Geraghty et al. Aug 2014 B2
8858624 Christie et al. Oct 2014 B2
8864824 Silvestrini et al. Oct 2014 B2
8955968 Zalevsky et al. Feb 2015 B2
9005281 Christie et al. Apr 2015 B2
9138142 Christie et al. Sep 2015 B2
9204962 Silvestrini Dec 2015 B2
9358103 Wortz Jun 2016 B1
9427311 Christie et al. Aug 2016 B2
9427922 Reboul et al. Aug 2016 B2
9492272 Christie et al. Nov 2016 B2
9545303 Vilupuru et al. Jan 2017 B2
9573328 Reboul et al. Feb 2017 B2
9603704 Silvestrini Mar 2017 B2
9744077 Zicker et al. Aug 2017 B2
9757227 Kushlin et al. Sep 2017 B2
9844919 Reboul et al. Dec 2017 B2
9848979 Vilupuru et al. Dec 2017 B2
9943403 Webb et al. Apr 2018 B2
9987127 Bogaert et al. Jun 2018 B2
10004593 Webb et al. Jun 2018 B2
10183453 Reboul et al. Jan 2019 B2
10342656 Vilupuru et al. Jul 2019 B2
10350058 Silvestrini Jul 2019 B2
10426600 Coleman et al. Oct 2019 B2
10449036 Christie et al. Oct 2019 B2
10548717 Webb et al. Feb 2020 B2
10583619 Reboul et al. Mar 2020 B2
10687935 Webb et al. Jun 2020 B2
10765508 Vilupuru et al. Sep 2020 B2
10869752 Christie et al. Dec 2020 B2
10932902 Reedy et al. Mar 2021 B2
10939995 Silvestrini Mar 2021 B2
11311371 Webb et al. Apr 2022 B2
11357617 Christie et al. Jun 2022 B2
11364110 Webb Jun 2022 B2
20010027314 Peyman Oct 2001 A1
20010034516 Peyman Oct 2001 A1
20010040740 Funakoshi Nov 2001 A1
20010050750 Breger Dec 2001 A1
20020010510 Silverstrini Jan 2002 A1
20020082288 Horn Jun 2002 A1
20020120329 Lang et al. Aug 2002 A1
20020128710 Eggleston Sep 2002 A1
20020167640 Francis et al. Nov 2002 A1
20020196409 Jani Dec 2002 A1
20030014042 Juhasz et al. Jan 2003 A1
20030060880 Feingold Mar 2003 A1
20030105521 Perez Jun 2003 A1
20030135272 Brady et al. Jul 2003 A1
20030149480 Shadduck Aug 2003 A1
20030204258 Graham et al. Oct 2003 A1
20030216763 Patel Nov 2003 A1
20040019379 Glick et al. Jan 2004 A1
20040056371 Liao et al. Mar 2004 A1
20040068317 Knight Apr 2004 A1
20040106929 Masket Jun 2004 A1
20040140578 Kelly et al. Jul 2004 A1
20050027355 Murakami et al. Feb 2005 A1
20050046794 Silvestrini et al. Mar 2005 A1
20050056954 Devlin Mar 2005 A1
20050090895 Peyman Apr 2005 A1
20050124983 Frey et al. Jun 2005 A1
20050134793 Roffman Jun 2005 A1
20050137703 Chen Jun 2005 A1
20050143751 Makker et al. Jun 2005 A1
20050143813 Hovey et al. Jun 2005 A1
20050182488 Peyman Aug 2005 A1
20050182489 Peyman Aug 2005 A1
20050187621 Brady Aug 2005 A1
20050288784 Peyman Dec 2005 A1
20060064077 Peyman Mar 2006 A1
20060079959 Christie et al. Apr 2006 A1
20060113054 Silvestrini Jun 2006 A1
20060135477 Haitjema et al. Jun 2006 A1
20060184243 Yilmaz Aug 2006 A1
20060232665 Schowengerdt et al. Oct 2006 A1
20060235428 Silvestrini Oct 2006 A1
20060235514 Silvestrini Oct 2006 A1
20060241751 Marmo et al. Oct 2006 A1
20060247659 Moeller et al. Nov 2006 A1
20060265058 Silvestrini Nov 2006 A1
20060268226 Christie et al. Nov 2006 A1
20060268227 Christie et al. Nov 2006 A1
20060268228 Christie et al. Nov 2006 A1
20060268229 Silvestrini et al. Nov 2006 A1
20060270946 Silvestrini et al. Nov 2006 A1
20060271026 Silvestrini et al. Nov 2006 A1
20060271178 Christie et al. Nov 2006 A1
20060271179 Christie et al. Nov 2006 A1
20060271180 Christie et al. Nov 2006 A1
20060271181 Christie et al. Nov 2006 A1
20060271182 Christie et al. Nov 2006 A1
20060271183 Christie et al. Nov 2006 A1
20060271184 Silvestrini Nov 2006 A1
20060271185 Silvestrini Nov 2006 A1
20060274264 Christie et al. Dec 2006 A1
20060274265 Christie et al. Dec 2006 A1
20070021832 Nordan Jan 2007 A1
20070032866 Portney Feb 2007 A1
20070091472 Alkemper et al. Apr 2007 A1
20070092592 Chiang Apr 2007 A1
20070129797 Lang et al. Jun 2007 A1
20070225691 Silvestrini et al. Sep 2007 A1
20080033546 Liang Feb 2008 A1
20080077238 Deacon et al. Mar 2008 A1
20080100921 Nishikawa May 2008 A1
20080151183 Altmann Jun 2008 A1
20080208335 Blum et al. Aug 2008 A1
20080212030 Bentley et al. Sep 2008 A1
20080220214 Uozu et al. Sep 2008 A1
20080221674 Blum et al. Sep 2008 A1
20080221676 Coleman et al. Sep 2008 A1
20080255663 Akpek et al. Oct 2008 A1
20080269884 Vannoy Oct 2008 A1
20080306587 Your Dec 2008 A1
20090012505 Chernyak Jan 2009 A1
20090021692 Miller et al. Jan 2009 A1
20090287306 Smith et al. Jan 2009 A1
20090036880 Bischoff et al. Feb 2009 A1
20090048608 Boukhny et al. Feb 2009 A1
20090059168 Miller et al. Mar 2009 A1
20090069817 Peyman Mar 2009 A1
20090164008 Hong et al. Jun 2009 A1
20090171458 Kellan et al. Jul 2009 A1
20090187242 Weeber et al. Jul 2009 A1
20090204207 Blum et al. Aug 2009 A1
20090213326 Zhao Aug 2009 A1
20090222086 Lui et al. Sep 2009 A1
20090234448 Weeber et al. Sep 2009 A1
20090279048 Hong et al. Nov 2009 A1
20090306773 Silvestrini et al. Dec 2009 A1
20090323020 Zhao Dec 2009 A1
20100016961 Hong et al. Jan 2010 A1
20100016965 Hong et al. Jan 2010 A1
20100082017 Zickler et al. Apr 2010 A1
20100082100 Mikawa Apr 2010 A1
20100127412 Lake May 2010 A1
20100149618 Sprague Jun 2010 A1
20100208199 Levis et al. Aug 2010 A1
20100225014 Bille Sep 2010 A1
20100312336 Hong et al. Dec 2010 A1
20110029074 Reisin et al. Feb 2011 A1
20110037184 Shoji et al. Feb 2011 A1
20110040376 Christie Feb 2011 A1
20110051080 Bandhauer et al. Mar 2011 A1
20110125261 Portney May 2011 A1
20110140333 Schaper et al. Jun 2011 A1
20110166652 Bogaert Jul 2011 A1
20110172675 Danta et al. Jul 2011 A1
20110245919 Pettit Oct 2011 A1
20110251685 Chu Oct 2011 A1
20110292340 Shimizu et al. Dec 2011 A1
20120143325 Christie Jun 2012 A1
20120203239 Vukich et al. Aug 2012 A1
20120245683 Christie et al. Sep 2012 A1
20120309761 Chow et al. Dec 2012 A1
20120310338 Christie et al. Dec 2012 A1
20130053953 Silvestrini Feb 2013 A1
20130131795 Miller et al. May 2013 A1
20130147072 Bothe et al. Jun 2013 A1
20130190868 Kahook et al. Jul 2013 A1
20130238091 Danta et al. Sep 2013 A1
20130289543 Mordaunt Oct 2013 A1
20130324983 Liang Dec 2013 A1
20140121767 Simpson May 2014 A1
20140131905 Webb May 2014 A1
20140200666 Phillips Jul 2014 A1
20140277437 Currie Sep 2014 A1
20140336625 Fernandez Nov 2014 A1
20140343541 Scott et al. Nov 2014 A1
20140379078 Trindade Dec 2014 A1
20150025627 Christie et al. Jan 2015 A1
20150046094 Chaudhary et al. Feb 2015 A1
20150073549 Webb et al. Mar 2015 A1
20150177422 Liu et al. Jun 2015 A1
20150183173 Linhardt et al. Jul 2015 A1
20150250583 Rosen et al. Sep 2015 A1
20150366658 Christie et al. Dec 2015 A1
20160100938 Bogaert et al. Apr 2016 A1
20160297107 Shim et al. Oct 2016 A1
20170049560 Cherne Feb 2017 A1
20170143477 Christie et al. May 2017 A1
20170156850 Silvestrini et al. Jun 2017 A1
20180125639 Vilupuru et al. May 2018 A1
20180133990 Reboul et al. May 2018 A1
20180296322 Webb et al. Oct 2018 A1
20190076235 Webb et al. Mar 2019 A1
20190076241 Alarcon Heredia et al. Mar 2019 A1
20190193350 Gu et al. Jun 2019 A1
20190269499 Ellis Sep 2019 A1
20200000576 Christie et al. Jan 2020 A1
20200008932 Silvestrini Jan 2020 A1
20200179105 Waterhouse et al. Jun 2020 A1
20200253721 Cuevas et al. Aug 2020 A1
20200337831 Webb et al. Oct 2020 A1
20200337834 Webb et al. Oct 2020 A1
20210015604 Ma Jan 2021 A1
20210137674 Webb May 2021 A1
20210154002 Christie et al. May 2021 A1
20210244532 Silvestrini Aug 2021 A1
20210290373 Peyman et al. Sep 2021 A1
Foreign Referenced Citations (143)
Number Date Country
2004201751 May 2004 AU
1734305 Feb 2006 CN
1875895 Dec 2006 CN
100368846 Feb 2008 CN
101322663 Dec 2008 CN
102448404 May 2012 CN
101341426 Jul 2012 CN
203647535 Jun 2014 CN
2727410 Dec 1978 DE
4134320 Apr 1992 DE
0165652 Dec 1985 EP
0443094 Aug 1991 EP
1173790 Jan 2002 EP
1674049 Jun 2006 EP
1548489 Aug 2006 EP
2111822 Oct 2009 EP
2319457 May 2011 EP
2243052 Sep 2011 EP
2365379 Sep 2011 EP
2455799 May 2012 EP
2823789 Jan 2015 EP
2364457 Aug 2015 EP
2993514 Mar 2016 EP
2349150 Jul 2016 EP
2620687 Mar 1989 FR
2649605 Jan 1991 FR
1276003 Jun 1972 GB
2507465 May 2014 GB
62-167343 Jul 1987 JP
64-002644 Jan 1989 JP
H01-195852 Aug 1989 JP
H02-7954 Jan 1990 JP
04-158859 Jun 1992 JP
06-509731 Mar 1993 JP
H05-65340 Sep 1993 JP
06-502782 Mar 1994 JP
H07-067896 Mar 1995 JP
07-265340 Oct 1995 JP
08-103457 Apr 1996 JP
H09-502542 Mar 1997 JP
11-503657 Aug 1997 JP
07-178125 Jul 1998 JP
2000-047145 Feb 2000 JP
2002-537895 Nov 2002 JP
2003-502109 Jan 2003 JP
2004-510199 Apr 2004 JP
2004-538034 Dec 2004 JP
2005-533576 Nov 2005 JP
2007-516794 Jun 2007 JP
2007-523720 Aug 2007 JP
2008-506710 Mar 2008 JP
S59-54527 May 2008 JP
2013-501598 Jan 2013 JP
2015-077412 Apr 2015 JP
10-0335722 May 2002 KR
10-2012-0093837 Aug 2012 KR
2138837 Sep 1999 RU
110978 Mar 2011 RU
2456968 Jul 2012 RU
2457812 Aug 2012 RU
2459598 Aug 2012 RU
2493801 Sep 2013 RU
134049 Nov 2013 RU
134784 Nov 2013 RU
2500368 Dec 2013 RU
2511081 Apr 2014 RU
2517488 May 2014 RU
1380743 Mar 1988 SU
201103518 Feb 2011 TW
WO 8705797 Oct 1987 WO
WO 9503747 Feb 1995 WO
WO 9508135 Mar 1995 WO
WO 9635397 Nov 1996 WO
WO 9848715 Nov 1998 WO
WO 00025704 May 2000 WO
WO 00038594 Jul 2000 WO
WO 0051682 Sep 2000 WO
WO 0052516 Sep 2000 WO
WO 0070388 Nov 2000 WO
WO 2001010641 Feb 2001 WO
WO 0115779 Mar 2001 WO
WO 0117460 Mar 2001 WO
WO 0119364 Mar 2001 WO
WO 01082815 Nov 2001 WO
WO 02076320 Oct 2002 WO
WO 02102241 Dec 2002 WO
WO 03020177 Mar 2003 WO
WO 03022168 Mar 2003 WO
WO 03061518 Jul 2003 WO
WO 2004014969 Feb 2004 WO
WO 2004034917 Apr 2004 WO
WO 2004105588 Dec 2004 WO
WO 2004113959 Dec 2004 WO
WO 2005023154 Mar 2005 WO
WO 2005082265 Sep 2005 WO
WO 2006014738 Feb 2006 WO
WO 2006020638 Feb 2006 WO
WO 2006047534 May 2006 WO
WO 2006060380 Jun 2006 WO
WO 2006069012 Jun 2006 WO
WO 2006113377 Oct 2006 WO
WO 2006113411 Oct 2006 WO
WO 2006113563 Oct 2006 WO
WO 2006113564 Oct 2006 WO
WO 2007057734 Oct 2007 WO
WO 2007133384 Nov 2007 WO
WO 2007142981 Dec 2007 WO
WO 2008036671 Mar 2008 WO
WO 2008102096 Aug 2008 WO
WO 2009050511 Apr 2009 WO
WO 2009122409 Oct 2009 WO
WO 2009140080 Nov 2009 WO
WO 2009149060 Dec 2009 WO
WO 2010002215 Jan 2010 WO
WO 2010059214 May 2010 WO
WO 2010118469 Oct 2010 WO
WO 2011020074 Feb 2011 WO
WO 2011020078 Feb 2011 WO
WO 2011047076 Apr 2011 WO
WO 2011069059 Jun 2011 WO
WO 2011088107 Jul 2011 WO
WO 2012170066 Dec 2012 WO
WO 2011030509 Feb 2013 WO
WO 2013019871 Feb 2013 WO
WO 2013082545 Jun 2013 WO
WO 2013101793 Jul 2013 WO
WO 2013112589 Aug 2013 WO
WO 2013123265 Aug 2013 WO
WO 2014054946 Apr 2014 WO
WO 2014074610 May 2014 WO
WO 2014158653 Oct 2014 WO
WO 2014164056 Oct 2014 WO
WO 2014195059 Dec 2014 WO
WO 2015021323 Feb 2015 WO
WO 2015069927 May 2015 WO
WO 2015073718 May 2015 WO
WO 2015078271 Jun 2015 WO
WO 2015086611 Jun 2015 WO
WO 2016081493 May 2016 WO
WO 2015108156 Mar 2017 WO
WO 2017062316 Apr 2017 WO
WO 2017091520 Jun 2017 WO
WO 2019010178 Jan 2019 WO
Non-Patent Literature Citations (10)
Entry
“Extending Depth of Focus with Small Aperture Optics”, AcuFocus, IC 8, Small Aperture IOL, Jul. 2019, in pp. 2.
Internet Archive Wayback Machine; Aniridia Implants; downloaded from https://web.archive.org/web/20110824062840/http://www.morcher.com/nc/produkte/aniridiaimplants.html (Archived Aug. 24, 2011; printed on Feb. 5, 2015).
Guyton A.C., Textbook of Medical Physiology, 7th Edition, W.B. Saunders Company, Jan. 1986: Chapter 58, in 13 pages.
International Search Report and Written Opinion for PCT/US2016/63181 dated Mar. 31, 2017 in 9 pages.
Lu Xuequan, et al. “Radiation preparation and thermo-response swelling of interpenetrating polymer network hydrogel composed of PNIPAAm and PMMA”, Radiation Physics and Chemistry, vol. 57, Mar. 2000, pp. 477-480, XP002473596.
Patel, C.K., et al. “Imaging the macula through a black occlusive intraocular lens”. Arch. Ophthalmol. Oct. 2010; 128(10):1374-1376.
Yusuf, et al., “Inability to perform posterior segment monitoring by scanning laser ophthalmoscopy or optical coherence tomography with some occlusive intraocular lenses in clinical use”, J. Cataract Refract. Surg., Mar. 2012, 38: 513-518.
Yusuf, et al., “Occlusive IOLs for Intractable Diplopia Demonstrate a Novel Near-Infrared Window of Transmission for SLO/OCT Imaging and Clinical Assessment”. Investigative Ophthalmology & Visual Science, May 2011, 52(6): 3737-3743.
Reper-NN LTD, Instruction for Use. MOIL-lris Iris-intaocular polymer elastic lenses, dated Aug. 2017, in 8 pages.
Ferrari et al. “La keratopigmentation annnulaire (ou PresbyRing) dans la prise en charge de la presbytie: etude experimentale de faisabilite post-mortem chez l'animal”, Journal Francais d'Ophtalmologie, vol. 36, Issue 6, Jun. 2013, pp. 481-487.
Related Publications (1)
Number Date Country
20180338826 A1 Nov 2018 US
Provisional Applications (1)
Number Date Country
62259524 Nov 2015 US